Business
MannKind to Participate in Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today its attendance at two

About this update from Mannkind Corporation
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today its attendance at two upcoming investor conferences, at which MannKind’s Chief Executive Officer, Michael Castagna , PharmD, and Chief Financial Officer, Chris Prentiss will participate in fireside chats and in 1x1 meetings with investors. Leerink Partners 2026 Global Healthcare Conference in Miami Tuesday, March 10 , 3:40 p.m. ET Barclays 28 th Annual Global Healthcare Conference in Miami Wednesday, March 11 , 1:00 p.m. ET Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations . Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com . Contacts: Investor Relations Kate Miranda (617) 921-5461 Email: [email protected] Media Relations Christie Iacangelo (818) 292-3500 Email: [email protected] Source: MannKind
View stock analysis, news, and events for Mannkind Corporation
More from Mannkind Corporation
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Ac...
August 13, 2026
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of It...
July 29, 2026